Latest Administration News

Smartgroup Corporation Ltd reported a solid first half for 2025 with revenue up 7% and net profit rising 11%, powered by strong novated leasing growth amid shifting electric vehicle policies.

Mineral Resources Limited reported FY25 results highlighting record mining services earnings driven by Onslow Iron's ramp-up, offset by lithium challenges and significant impairments. The company is focused on deleveraging and strengthening governance as it transitions to long-life, low-cost assets.

Mineral Resources Limited posted a $896 million statutory loss for FY25, driven by significant impairments, while Onslow Iron achieved commercial production and governance reforms reshape the board.

Wesfarmers Limited has announced a fully franked ordinary dividend of AUD 1.11 per share for the half-year ending June 2025, offering shareholders multiple currency payment options and a Dividend Reinvestment Plan.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

SIV Capital Limited reported a statutory loss of $112,789 for the year ended June 2025, continuing its operational scale-down with only four active rental contracts. The company remains debt-free with $8.18 million in cash but its ASX securities remain suspended as it evaluates a confidential corporate opportunity.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.

Pengana International Equities has acknowledged breaching ASX disclosure rules by sharing details of a new private credit strategy with media before official announcement, prompting a policy overhaul.

Neuren Pharmaceuticals reported a robust half-year with an 88% increase in net profit, driven by rising royalties from DAYBUE™ sales and progress in its NNZ-2591 clinical program. The company also completed a $39.6 million share buy-back, underscoring confidence in its growth trajectory.